Griesinger Frank, Thomas Michael
Pius Hospital Oldenburg, Medizinischer Campus Universität Oldenburg, Klinik für Hämatologie und Onkologie, Universitätsklinik für Innere Medizin - Onkologie, Oldenburg.
Internistische Onkologie Thorakaler Tumoren, Thoraxklinik am Universitätsklinikum Heidelberg, Heidelberg.
Pneumologie. 2021 Sep;75(9):641-643. doi: 10.1055/a-1486-9057. Epub 2021 Sep 15.
Therapy of non-small cell lung cancer (NSCLC) should be based on biomarker test results in the palliative setting. To this end, testing of all patients in stage IV and in the future also in the earlier stages will be important. In a conference with the patronage of the German Cancer Society, the question of "reflex testing", i. e. independently of tumor stage, was discussed but not deemed to be acceptable. The current report summarizes the results of the consensus conference and discusses possible paths to efficent biomarker testing in NSCLC.
非小细胞肺癌（NSCLC）的治疗应基于姑息治疗环境下的生物标志物检测结果。为此，对所有IV期患者进行检测，未来对更早阶段的患者进行检测也将很重要。在德国癌症协会赞助的一次会议上，讨论了“反射性检测”问题，即不考虑肿瘤分期的检测，但该问题未被认为是可接受的。本报告总结了共识会议的结果，并讨论了NSCLC中有效生物标志物检测的可能途径。
